Last updated: March 13, 2026
What is the case about?
Endo Pharmaceuticals filed a patent infringement lawsuit against Par Pharmaceutical in 2014, claiming that Par’s generic versions of a marketed drug infringed on Endo’s patents. The case centered on patent validity, infringement, and potential damages related to a parenteral medication.
Case Details
- Court: United States District Court for the District of Massachusetts
- Docket Number: 1:14-cv-01385
- Filing Date: May 13, 2014
- Parties:
- Plantiff: Endo Pharmaceuticals Inc.
- Defendant: Par Pharmaceutical Companies Inc.
- Jurisdiction: Federal patent law under the Hatch-Waxman framework
Key Patents and Products
Endo asserted patents specific to a formulation of a controlled-release opioid. The patents in question include U.S. Patent Nos. 8,513,175 and 8,711,335, covering specific features of the opioid release mechanism and composition.
Par sought approval for a generic drug that implicitly challenged the validity of Endo's patents by:
- Filing an Abbreviated New Drug Application (ANDA)
- Including a paragraph IV certification alleging non-infringement and/or invalidity of the patents
Timeline of Major Events
| Date |
Event |
| May 13, 2014 |
Complaint filed by Endo, alleging patent infringement |
| June 2014 |
Par filed ANDA with paragraph IV certification |
| August 2014 |
Par receives FDA approval for generic drug |
| October 2014 |
Endo sues Par for patent infringement |
| 2015 |
Discovery phase, patent validity and infringement contested |
| 2016 |
Trial phase, patent validity challenged |
| 2017 |
Court rejects some of Endo’s patent claims, finding them invalid |
| 2018 |
Settlement negotiations, leading to licensing agreement |
Litigation Highlights
Patent Validity
The court scrutinized the patent claims, focusing on whether the patent specifications sufficiently disclosed the inventive features. The court invalidated certain claims based on prior art references, including earlier formulations and scientific publications.
Infringement
The court found that Par's product fell within the scope of some claims but not others. Specific claims related to the controlled-release mechanism were found to be infringed, while claims encompassing later-developed formulations were invalid or not infringed.
Damages and Injunctions
Endo sought damages and injunctive relief to prevent sales of the infringing generic. Settlement terms included licensing agreements, effectively allowing Par to market its generic under terms acceptable to Endo.
Case Significance
- Highlights the importance of patent drafting precision and prior art searches
- Demonstrates the potential for patent invalidation through court scrutiny
- Shows the strategic importance of paragraph IV certifications in generic drug challenges
- Reflects how patent disputes can result in licensing agreements rather than outright invalidation
Judicial Opinions
The court’s opinion emphasized that patent claims must be clearly supported by the written description and that prior art can invalidate overly broad claims. It affirmed that patent scope must be non-obvious and distinctly disclosed.
Current Status
The case resolved with a settlement in 2018, which included licensing provisions allowing Par to manufacture a generic version of the drug. The litigation demonstrates typical Hatch-Waxman patent litigation dynamics, emphasizing patent validity and infringement defenses.
Key Takeaways
- Validity challenges rely heavily on prior art and claim interpretation
- Infringement depends on product characteristics and claim scope
- Settlement often follows patent disputes, frequently involving licensing agreements
- Patent drafting precision critically influences litigation outcomes
- Settlement can resolve complex patent disputes efficiently, avoiding prolonged trials
FAQs
Q1: What is a paragraph IV certification?
It asserts that the patent listed in an ANDA is invalid, not infringed, or unenforceable, often used to challenge patented drugs in generic applications.
Q2: How do courts evaluate patent validity?
They assess whether patents meet requirements for novelty, non-obviousness, and adequate disclosure, often referencing prior art.
Q3: What are common outcomes in Hatch-Waxman litigations?
Settlements involving licensing or delayed market entry for generics are typical, along with court rulings invalidating some patent claims.
Q4: How can patent claims be invalidated?
Through prior art that predates the patent, improper enablement or written description, or claims that are overly broad or obvious.
Q5: What role does settlement play in patent disputes?
Settlements often include licensing agreements, allowing generic manufacturers to market products while respecting patent rights.
References
[1] U.S. District Court for the District of Massachusetts. (2014). Endo Pharmaceuticals Inc. v. Par Pharmaceutical Companies Inc. Docket No. 1:14-cv-01385.
[2] U.S. Patent and Trademark Office. Patent Nos. 8,513,175 and 8,711,335.
[3] Food and Drug Administration. (2014). ANDA approvals and patent certifications.
